In Vitro to In Vivo Extrapolation Linked to Physiologically Based Pharmacokinetic Models for Assessing the Brain Drug Disposition

Yukiko Murata,1,2 Sibylle Neuhoff,3 Amin Rostami-Hodjegan,1,3 Hiroyuki Takita,1,4 Zubida M. Al-Majdoub,1 and Kayode Ogungbenro1,5

Received 22 September 2021; accepted 9 December 2021; published online 13 January 2022

Abstract. Drug development for the central nervous system (CNS) is a complex endeavour with low success rates, as the structural complexity of the brain and specifically the blood-brain barrier (BBB) poses tremendous challenges. Several in vitro brain systems have been evaluated, but the ultimate use of these data in terms of translation to human brain concentration profiles remains to be fully developed. Thus, linking up in vitro-to-in vivo extrapolation (IVIVE) strategies to physiologically based pharmacokinetic (PBPK) models of brain is a useful effort that allows better prediction of drug concentrations in CNS components. Such models may overcome some known aspects of inter-species differences in CNS drug disposition. Required physiological (i.e. systems) parameters in the model are derived from quantitative values in each organ. However, due to the inability to directly measure brain concentrations in humans, compound-specific (drug) parameters are often obtained from in silico or in vitro studies. Such data are translated through IVIVE which could be also applied to preclinical in vivo observations. In such exercises, the limitations of the assays and inter-species differences should be adequately understood in order to verify these predictions with the observed concentration data. This report summarizes the state of IVIVE-PBPK-linked models and discusses shortcomings and areas of further research for better prediction of CNS drug disposition.

KEY WORDS: central nervous system; blood-brain barrier; drug transporters; lipophilicity; tissue concentrations.

INTRODUCTION

Drug development is costly and improving the productivity requires more rationale progression of compounds with high viability to advanced phases of development. It is estimated that 90% of industry R&D expenditure goes into molecules that never reach the market (1). Hence, making the right decision on what to progress to late-stage clinical trials is essential. The rate of failure is similar for most therapeutic areas, but particularly neuroscience has been deemed a more difficult area with lower rate of success (1,2). Whilst a large part of this relates to lack of good experimental models mimicking relevant mechanisms of the disease, the difficulties associated with the location of the drug effect, namely central nervous system (CNS), cannot be dismissed. Unlike many other organs in which drugs in the systemic circulation readily diffuse, there is a blood-brain barrier (BBB) and a blood-CSF barrier (BCSFB) in the brain that control drug diffusion within and outside the brain. Particularly, BBB has many features that makes establishing relationship between the drug concentrations in systemic circulation and in CNS more challenging. The BBB tightly regulates the exchange of molecules with systemic circulation via its micro-structure and transport proteins. Although, pre-clinical animal models (mainly rodents) are used in neuroscience and neurotoxicity research, the abundance and nature of the transporters in rodents vary from humans (3,4). Consideration of such inter-
species differences are important in the translation of observations in animals to expected outcomes in humans. A physiologically-based pharmacokinetic (PBPK) modelling framework is suggested that requires quantitative knowledge of transport (passive and active) in each species, the experimental affinity of the molecules to various transporters, and 'local exposure' in animals that be projected to expected toxicological or pharmacological effects in humans (3) (Fig. 1).

PBPK models based on human physiology allow prediction of drug concentrations in target tissues, which has been well documented and have become a critical tool in nonclinical and clinical study design and regulatory review. At the same time, CNS PBPK models have been reported based on various types of model structures and parameter acquisition methods. Physiological parameters in the model are generally derived from intrinsic quantitative values in each organ, while compound-specific parameters are derived based on in silico or in vitro experiments and translated via in vitro-to-in vivo extrapolation (IVIVE), and may include preclinical in vivo results too (5). In this review, we describe the structure of the CNS, factors that determine the central distribution of drugs, and methods for experimental evaluation. In addition, differences among published brain PBPK models are highlighted and compared, to provide a perspective for CNS evaluation using the brain IVIVE-PBPK model.

STRUCTURE OF THE CNS

CNS consists of the brain and spinal cord, surrounded by meninges and skull (6). The spaces between the arachnoid membrane and spinal cord or brain, including the ventricles, are filled with medium called spinal or cranial cerebrospinal fluid (CSF), respectively. Interstitial fluid (ISF) occupies intercellular space of the brain (20% of the total brain volume of around 1250 mL in humans (7,8)), mediating the exchange of drugs between brain cells and CSF. Microvessels, which are intricately branched from cerebral arteries, carry oxygen and nutrients from blood to the brain, while microvessel endothelial cells prevent the penetration of harmful substances into the brain by forming tight junctions, adherens junctions and the BBB. Endothelial cells of the choroid plexus and arachnoid membrane work as another barrier between blood and CSF (blood-cerebrospinal fluid barrier, BCSFB), with a significant smaller surface area than the BBB (~50% of BBB (9)). Since predominantly protein-unbound unionized drugs penetrate these barriers, the distribution of drugs in the brain is determined by factors like the pH (pH: 7.3(10)) or protein content (~0.2 g/L (8,11)) of CSF/ISF and plasma. In addition to the limitation in passive permeation, active (blood orientated) efflux carriers located in the BBB and BCSFB work as second defense system for the brain by excreting drugs out of the brain. After reaching the brain, drugs distribute throughout the CNS by the flow of CSF (0.2–0.4 mL/min in human (8,12)). Produced in the choroid plexus, CSF ascends to the superficial subarachnoid space or down the spinal space, and is finally absorbed by various routes such as arachnoid granules or lymphatic vessels. The total CSF (140 mL in human) is replaced 2–4 times per day (6,8). To explain drug disposition in the brain, it is necessary to understand not only properties of the drug itself, but also these physiology of CNS; physiological parameters such as volumes of micro-compartments or flow rates of mediums in human and aminals as summarised previously (10,12). For drugs targeting CNS diseases, it is also important to consider the influence of the diseases on the physiology of the brain; CNS diseases such as stroke, brain tumor, and meningitis, as well as aging, may change barrier function (BBB, BCSFB) or composition and/or flow rate of the CSF and/or ISF, leading to altered drug disposition in the brain (6,7).

TECHNIQUES TO ESTIMATE BRAIN DISTRIBUTION OF CNS AND TRANSPORT ACROSS THE BBB

Several approaches have been developed to evaluate membrane permeability and pharmacokinetic (PK) in the brain, including in vivo, in vitro, ex vivo, and in silico methods (Table I). This part summarizes the methods useful for understanding brain distribution and discusses the approaches currently predominantly used for CNS exposure prediction.

Positron Emission Tomography (PET)

PET is a non-invasive method for measuring concentrations of positron emitting radioisotopes. Imaging by PET allows the Kp,brain (total concentration ratio of the brain to plasma) of the radiolabelled drugs to be determined in humans (13–15). The method cannot distinguish between free and bound compounds and metabolites from parent compounds. In addition, since it targets the brain, it must be a highly lipophilic compound, but non-specific adsorption may occur, also there are limitations such as the short half-life of isotopes used in PET. Consequently, PET data are only available for a limited number of CNS drugs (16).

In Vivo Microdialysis

The unbound extracellular concentration and time profiles in each CNS compartment provide important information for drug distribution, but the only way to know this information in vivo is by microdialysis. The unbound volume of distribution in the brain (Vu,brain) determined by microdialysis (Vu,brain,MD) is calculated by dividing the amount of drug in the brain (Abrain) measured by conventional brain tissue sampling by the unbound drug concentration in the brain ISF (Cu,brainISF) measured by microdialysis in the same animal (Eq. 1)(17).

\[
V_{u,brain,MD} = \frac{A_{brain}}{C_{u,brain,ISF}}
\]

In Vitro Brain Slice Methods

The brain slice method was originally developed by Kakee et al.(18) and further refined by Friden (17). The high-throughput brain slice method is a precise and robust technique for estimating the overall uptake of drugs into brain tissue through determination of the unbound volume of distribution in the brain (Vu,brain; ml g brain$^{-1}$) (19). By measuring concentrations in brain slices and buffers at steady state, unbound Vu,brain can be calculated without the need for microdialysis. The brain slice method is more physiologically based than the brain homogenate method with respect to the assessment of drug distribution.
distribution in the brain since active transport systems, pH gradients, and cell-cell interactions are conserved. The method provides information relevant to nonspecific binding to brain tissue, lysosomal trapping, and active uptake into the cells. For these reasons, the brain slice method is suitable for estimation of target-site PK in the early drug discovery process and fundamental pharmacological studies.

In Vitro Brain Homogenate Assay

The brain homogenate binding method measures the intracellular binding by equilibrium dialysis of diluted brain homogenates and allows estimation of V_u,brain. The fraction of unbound drug in diluted brain homogenate, f_u,hD, i.e. the buffer-to-homogenate concentration ratio, is used to calculate f_u,brain, while also taking into account the dilution (D) associated with homogenate preparation (Eq. 2)(20). The inverse of f_u,brain (V_u,brain(h)) is used to express the quantity on the V_u,brain scale (Eq. 3)(17).

\[
f_{u,brain} = \frac{1}{1 + D(f_{u,hD} - 1)}
\]

\[
V_{u,brain(h)} = \frac{1}{f_{u,brain}}
\]

In Situ Brain Perfusion

A widely used method to measure the permeability of the BBB in vivo is the in situ brain perfusion technique. The in situ perfusion method was originally developed by Takasato for the rat (21). However, it has been expended to be used in mice, guinea pigs and rabbits. This method generates a permeability surface area-product (PS) in ml/s/g (brain weight). PS could be converted into in vivo brain permeability values (Pe in vivo in cm/s) by dividing PS by an estimated value of the surface area (S) of perfused capillaries equal to 150 cm²/g of brain in rat (22).

BBB Cell Models

Cell Culture Models to Estimate Transporter Kinetics

Standard permeability systems in the industry are Caco-2, MDCK and LLC-PK₁ cell systems. However, there are several sources of these three cell systems (23), hence a comparison between these systems is often challenging. Users of this models often rely on in-house experience and correlations. The systems are well-established and regularly used for the estimates of intestinal permeability in general research and for regulatory submissions. It is therefore not surprising that these systems, although epithelial cell based, are tested to be used to give not only transporter kinetic data, but also permeability estimates for the BBB (24). Transporter kinetic obtained from such cell systems (mostly MDCK-MDR1, LLC-PK₁-MDR1, MDCK-BCRP, and Caco-2), specifically when they are only driven by ATP-dependent transporter like MDR1 and BCRP, can be used, since the functionality of these transporters in the brain as matrix is unlikely different to the functionality in the in vitro cell system (as long as the driving force, i.e. ATP is supplied) (25,26). The passive permeability, however, may be different and the user should be aware of the assumptions made, when using these in vitro systems to estimate the passive permeability across the BBB.

Brain Uptake Index and Brain Efflux Index Methods

The brain uptake index (BUI) is defined as the relative percentage of uptake of the test compound and reference compound injected and easily penetrate the brain but not for...
| Method | Measured/Estimated Parameter | Advantages | Disadvantages |
|--------|-----------------------------|------------|---------------|
| **In vivo methods** | | | |
| Intravenous injection/brain sampling | Influx; influx & efflux | Most physiological approach | Not simple to discriminate unidirectional uptake from bidirectional transfer. |
| | | Highest sensitivity | | |
| | | Low technical difficulty | | |
| Brain uptake index (BUI) | Influx | Fast procedure | Relatively insensitive (compared with intravenous injection and brain perfusion) |
| | | Moderate technical difficulty | | |
| BUI is defined as the relative percentage of uptake of the test compound and reference compound injected into the brain | | Permits wide range of modifications of injectate composition | | |
| | | Artifacts by metabolism largely excluded | | |
| Brain efflux index (BEI) | Efflux | Moderate technical difficulty | Technically more difficult and invasive than intravenous experiments. |
| BEI is defined as the relative percentage of drug efflux from the ipsilateral cerebrum. | | Permits wide range of modifications of injectate composition | | |
| | | Artifacts by metabolism largely excluded | | |
| Brain perfusion | Influx | Higher sensitivity compared with BUI | Technically more difficult than intravenous experiments and BUI |
| | | Permits modification of both perfusate composition and flow rates | | |
| | | Artifacts by peripheral metabolism are excluded | | |
| Quantitative autoradiography | Influx | Excellent spatial resolution | Time-consuming evaluation |
| | | | No proof of integrity of tracer |
| External registration: MRI, SPECT, PET | Influx & efflux; $K_{p, brain}$ | Noninvasive and applicable in humans | Expensive equipment (MRI, PET) and tracers (PET) |
| | | Allows time course measurements in individual subjects | Limited sensitivity (MRI) and availability of labeled tracers (MRI, PET) |
| Microdialysis | Influx & efflux; $V_{u,brain, MD}$ | Allows time course measurements in individual subjects | Poor spatial resolution for small animals (SPECT) |
| | | Samples well suited for subsequent analytical procedures | | |
| CSF sampling | Influx & efflux | Readily accessible for sampling; Applicable to humans | | |
| | | | Reflects permeability of BCSFB and CSF fluid dynamics rather than BBB |
| **In vitro methods** | | | |
| Brain slices | Uptake; $V_{u,brain}$ | High-throughput method has been developed; Active transport systems, pH gradients, and cell-cell interactions are conserved. The method provides information relevant to nonspecific binding to brain tissue, lysosomal trapping, and active uptake into the cells. The method is suitable for estimation of target-site pharmacokinetics in the early drug discovery process and fundamental pharmacological studies. | | |
| | | | Technically more difficult than intravenous experiments and BUI. Technical skill is required |
| Brain homogenate | $f_{u,brain}$; | | |
| Method                             | Measured/Estimated Parameter | Advantages                                                                 | Disadvantages                                                                 |
|-----------------------------------|-----------------------------|-----------------------------------------------------------------------------|------------------------------------------------------------------------------|
| Fresh isolated brain microvessels | Binding, uptake, efflux     | Represents the in vivo expression of transporters and efflux systems at the BBB | Transcellular passage cannot be measured                                      |
| EC membrane vesicles              | Carrier-mediated transport  | Allows distinction of luminal versus abluminal transport activity            | Large amounts of source material required laborious preparation                |
| Endothelial cell culture          | Receptor binding            | Permeability screening experiments (feasible with primary EC from bovine/porcine sources) | No system yet able to represent in vivo condition with respect to barrier tightness and BBB specific transporter expression |
| Primary cultures, cell lines      | Uptake, luminal to abluminal transfer (and opposite direction) | Effect of culture conditions on BBB transport properties may be studied (e.g., astroglial factors, serum effects, inflammatory stimuli, hypoxia/aglycemia) | Multitude of models makes comparison of results between studies difficult       |
| Epithelial cell culture           | Uptake, efflux, bidirectional transport | Permeability screening experiments, Transporter kinetics, Simple systems that are routinely established in industry | Not all transporters will function the same in the epithelial system versus the BBB, The passive transcellular and paracellular pathways are different in epithelial and endothelial cells |
| Artificial membranes              | Passive permeability        | High-throughput method                                                       | No information on active transport or metabolism                              |
| Parallel artificial membrane permeability assay (PAMPA) | CNS active (+/-) | Screening of large compound libraries (depending on model selection and computational resources) | Many current models based on data, which may not represent BBB permeability as such (log BB; CNS activity) |
| In silico models                  | Log BB                      | Screening of virtual libraries                                               | Still very limited data bases for BBB transport (log PS models)               |
| QSAR                              | Log PS                      |                                                                             |                                                                               |
poorly penetrating compounds (27). The Brain Efflux Index (BEI) is defined as the relative percentage of drug efflux from the ipsilateral cerebrum (18). These methods allow investigation of carrier-mediated BBB transport.

**Parallel Artificial Membrane Permeability Assay (PAMPA)**

Several PAMPA for the brain have been developed (28, 29). It is a method which determines the permeability of substances from a donor compartment, through a lipid-infused artificial membrane into an acceptor compartment. PAMPA-BBB cannot account for transporter effects and is solely representing an artificial membrane that mimics the BBB to estimate the passive permeation at that barrier.

**In Silico Quantitative Structure Activity Relationship (QSAR) Models**

Numerous QSAR models have been developed for predicting the log BB (the logarithm value of brain to blood concentration ratio) (30–32) and the log PS (the logarithm value of permeability surface area product) (33–35). As data in humans are sparse these QSAR models are generally established based upon non-human, generally rat data. Consequently, a correction is required when extrapolating these predictions to humans.

**PBPK MODELS FOR BRAIN**

Broadly, in increasing order of complexity models in PK can be classified into empirical, semi-mechanistic and mechanistic (PBPK) models (36). This classification is also based on the amount and quality of data required and the intended goal of the analysis. An empirical model development is based on a broad understanding of human physiology, the body is assumed to be composed of 1, 2 or 3 homogeneous compartments. This approach is mostly top down, data driven and limited in usage. The semi-mechanistic model development incorporates mechanistic understanding of certain components of the body, which allows the developer to focus on specific area of the body and also helps to reduce complexity. Some parameters of these models are supported by anatomy and physiology and in vitro/in silico experiments, the rest are estimated from in vivo data. The PBPK modelling on the other hand is based on mechanistic understanding of the physiology of the body; various tissues and organs are represented as compartments, volumes are actual physiological volumes and connections are by physiological flows. PBPK modelling is often based on a bottom up approach, where data from in vitro and in silico experiments are intergrated with other physiological data during development. Consequently, PBPK models are generally very rich in information content and can be used in wider scenario, especially for extrapolation during drug development (37). The advancement of methodologies for integrating in vitro and in silico data under IVIVE paradigm together with PBPK models in the last 20 years has increased the usefulness and application of PBPK models (5).

Based on the structure of central nervous system presented above, published models in the literature for description/prediction of brain exposure of drugs in animals and humans will be discussed in this review. Table II gives a summary of literature models these categories: empirical, semi-mechanistic or PBPK (IVIVE) models. The table also states the model properties such as the specimen the model was developed for, data available during development, the structure of the model (compartments for brain and CSF), model parameter for active transport and how this parameter was derived, how the model for the rest of the body was handled, i.e. disposition and the source of data. In most cases, the models have been developed in rats, due to the need to obtain samples during the experiment from the brain and CSF in addition to blood for accurate characterisation of disposition in the CNS. This includes microdialysis experiments, which allows direct quantification of endogenous and exogenous substances in different regions of the central nervous system such as the CSF regions, intracellular and extracellular areas. Also, terminal brains and CSF concentrations have been used as sources of data for model development in animals. For the CSF model developed based on human data, human CSF and brain samples in disease population in addition to plasma data have been used (38, 39).

**Empirical Models**

These models are generally obtained by fitting experimentally obtained in vivo plasma or blood, brain and CSF data in animals to empirically determined number of compartments. Physiological parameters such as tissue volumes or flows are not used or fixed, and these model have limited use since extrapolation especially between species have to be done with caution. An example of this type of model is the 4-compartment model developed for characterisation of the PK of morphine in male rats following short intravenous infusions, with and without continuous intravenous infusion of a MDR1 inhibitor (GF120918) (40). Total blood and unbound extracellular concentrations of morphine obtained by intra-cerebral microdialysis were used for the modelling. The model also included a 3-compartment for blood PK, which was not influenced by the MDR1 inhibitor and a 1-compartment model for unbound extracellular fluid (ECF) disposition obtained by microdialysis. The model included a parameters for passive diffusion and active saturable efflux and also nonlinear dose dependent distribution into the brain was captured.

**Semi-mechanistic Models**

These models use knowledge of anatomy and physiology of the central nervous system to determine the structure and number of compartments for the model. Parameters of these models are either fixed to physiological values or estimated from the available in vivo data. This middle out approach combines prior information about the anatomy and physiology of the system with the information available in the in vivo data, this allows physiological interpretation of estimated parameters of the model. Ooie et al. (41) characterised the CNS distribution of quinolone antibiotics in rats using blood, CSF and whole brain terminal samples. With other parameters fixed to physiological values, permeability clearances across the BBB and BCSFB were estimated and used to provide evidence for efflux of quinolones across the BBB. Takasawa et al. (42) used the same
| No | Species | Brain model structure | Passive transport | Transporter mediated transport |
|----|---------|-----------------------|-------------------|--------------------------------|
|    |         | Brain blood/ plasma ISF (ECF) | ICF | CSF | Parameter estimation (in vivo) | Parameter estimation (in vivo) |
| 1  | rat     | x x                   | - | - | Parameter estimation (in vivo) | Parameter estimation (in vivo) |
| 2  | rat     | x x(2 compartments) | x | x | Parameter estimation (in vivo) | Parameter estimation (in vivo) |
| 3  | rat     | x x                   | - | x | Parameter estimation (in vivo) | Parameter estimation (in vivo) |
| 4  | rat     | x x                   | x | x | Parameter estimation (in vivo) | Parameter estimation (in vivo) |
| 5  | rat     | x x                   | x | x | Parameter estimation (in vivo) | Parameter estimation (in vivo) |
| 6  | rat     | x(extravascular, intravascular) | x | - | Parameter estimation (in vivo) | Parameter estimation (in vivo) |
| 7  | rat, (human : simulation only) | x x | x | x | Parameter estimation (in vivo) | Parameter estimation (in vivo) |
| 8  | rat,human | x x (brain cells) | x(LV,TFV,CM,SAS) | Parameter estimation (in vivo) | Parameter estimation (in vivo+inhibitor) |
| 9  | rat,dog human child, human adult | x x (brain deep) | x(LV,TFV,CM,SAS) | Parameter estimation (in vivo) | Parameter estimation (in vivo+inhibitor) |
| 10 | rat,human | x x | x | x | Parameter estimation (in vivo) | Parameter estimation (in vivo) |
| 11 | rat,human | x(x(microvascular)) | x/lysosome | x(LV,TFV,CM,SAS) | Parameter estimation (in vivo) | Parameter estimation (in vivo) |
| 12 | rat human | x x | x/lysosome | x(LV,TFV,CM,SAS) | Parameter estimation (in vivo) | Parameter estimation (in vivo+inhibitor) |
| 13 | human | x(x(microvascular)) | x/lysosome | x(LV,TFV,CM,SAS) | Parameter estimation (in vivo) | Parameter estimation (in vivo+inhibitor) |
| 14 | mouse | x x | - | - | Parameter estimation (in vivo) | Parameter estimation (in vivo) |
| 15 | rat, (human : simulation only) | x(x(vascular)) | x | - | Parameter estimation (in vivo) | Parameter estimation (in vivo) |
| 16 | rat | x x | x | x | Parameter estimation (in vivo) | Parameter estimation (in vivo) |
| 17 | rat,human | x x | x | - | Parameter estimation (in vivo) | Parameter estimation (in vivo) |
| 18 | mouse,rat | x(x(vascular, intravascular)) | x | - | Parameter estimation (in vivo) | Parameter estimation (in vivo) |
| 19 | human | x x | - | (CSF, choroidplexus) | Parameter estimation (in vivo) | Parameter estimation (in vivo) |
| 20 | human | x x | x | (cranial,spinal) | Parameter estimation (in vivo) | Parameter estimation (in vivo) |
| 21 | rat,human | x(x(hippocampus/frontal cortex)) | - | - | Parameter estimation (in vivo) | Parameter estimation (in vivo) |
| 22 | rat,human | x (hippocampus/frontal cortex) | x | - | Parameter estimation (in vivo) | Parameter estimation (in vivo) |
| 23 | human child, human adult | x | x (rest of brain tissue) | x | Parameter estimation (in vivo) | Parameter estimation (in vivo) |
Table II. (continued)

| No | Volume of each compartment | Rat PK data | Human PK data | Compound | Platform | Refs |
|----|---------------------------|-------------|---------------|----------|----------|------|
| 1  | Parameter estimation      | MD          | -             | Morphine | NONMEM vV | (40) |
|    | (in vivo)                 |             |               |          |          |      |
| 2  | Parameter estimation      | MD          | -             | Fluvoxamine | NONMEM vV | (81) |
|    | (in vivo)                 |             |               |          |          |      |
| 3  | Parameter estimation      | MD          | -             | Quinolones | MULTI    | (41) |
|    | (in vivo)/Physiological values |          |               |          |          |      |
| 4  | Brain slice/Physiological values | in vivo PK | -             | 3’-Azido-3’-deoxythymidine, 2’,3’-Dideoxyinosine | MULTI | (42) |
| 5  | Brain slice               | MD          | -             | Morphine, morphine-6-h-d-glucuronide | WinNonlin v4.1 | (43) |
| 6  | Parameter estimation      | MD          | -             | Caffeine, fluoxetine, propranolol, theobromine, theophylline, NFPS, CP-141938 | WinNonlin v3.2 | (44) |
|    | (in vivo)/brain homogenate | in vivo PK | -             |          |          |      |
| 7  | Physiological values      | MD          | -             | Duloxetine, Atomoxetine | NONMEM vV | (45) |
| 8  | Physiological values      | MD          | x             | Paracetamol | NONMEM v6.2 | (46) |
| 9  | Physiological values      | MD          | -             | Quinidine | NONMEM v6.2 | (47) |
| 10 | Physiological values      | MD          | x             | Methotrexate | NONMEM v6.2 | (48) |
| 11 | Physiological values      | MD          | x             | Paracetamol, Atenolol, Methotrexate, Morphine, Quinidine, Remoxipride, Paliperidone, Phenytoin, Risperidone | NONMEM v7.3 | (49) |
| 12 | Physiological values      | MD          | -             | Paracetamol, Atenolol, Methotrexate, Morphine, Quinidine, Remoxipride, Paliperidone, Phenytoin, Risperidone, Raclopride | NONMEM v7.3 | (50) |
| 13 | Physiological values      | -           | x             | Paracetamol, Oxycodone, Morphine, Phenytoin | NONMEM v7.3 | (51) |
| 14 | Physiological values      | -           | -             | Dompereidone | S-Plus | (55) |
| 15 | Physiological values      | MD          | x(plasma)     | Morphine, Oxycodone | acslX | (57) |
| 16 | Physiological values      | MD          | -             | Paracetamol, atomoxetine, S 18986 | WinNonlin v6.3 | (58) |
| 17 | Physiological values      | MD          | x(plasma)     | Anonymous | WinNonlin v6.3 | (59) |
| 18 | Physiological values      | MD          | -             | norfloxacin | Matlab v8.1 | (60) |
| 19 | Physiological values      | -           | x             | Paracetamol, Phenytoin | Simcyp Simulator v14 | (38) |
| 20 | Physiological values      | -           | x (Glioblastoma Patients) | Anonymous | Simcyp Simulator v16 | (39) |
| 21 | Physiological values      | -           | x             | Clozapine, Haloperidol, Oxazepam, Paliperidone, Quetiapine, Risperidone | NONMEM vVI | (71) |
| 22 | Physiological values      | MD          | x             | Phenytoin, Carbamazepine, Morphine | Matlab v9.1 | (60) |
| 23 | Physiological values      | -           | x             | Paracetamol, Ibuprofen, Flurbiprofen, Naproxen, Meropenem | R v1.1.442 | (61) |

*ECF* brain extracellular fluid, *ICF* brain intracellular fluid, *REF* relative transporter expression factor, *ER* efflux ratio, *LV* lateral ventricle, *TFV* the third and fourth ventricle, *CM* the cisterna magna, *SAS* the subarachnoid space, *MD* microdialysis
model as Ooie et al. (41), to characterise the distribution of 3'-azido-3'-deoxycytidine and 2',3'-dideoxynosine in brain tissue and CSF. Bourasset et al., (43) developed a capacity-limited transport model for morphine and its metabolite, morphine-6β-D-glucuronide using blood, brain (intra and extracellular sampling) and CSF concentrations in rats. In this study, the in vivo data was obtained from a microdialysis experiment and some model parameters were informed by prior data from in situ experiments and physiology. The remaining parameters were estimated by fitting the model to the observed data. Liu et al., (44) developed a hybrid brain PBPK model for seven compounds in rats using plasma and in situ brain data, with the assumption that there is no significant contribution to the disposition in the brain of the compounds under investigation by any transporter. Physiological parameters such as the volume and blood flow of rat brain were obtained from physiological data and other parameters for brain disposition were estimated from the in vivo data. Also, parameters derived from this model were correlated with corresponding parameters derived from in situ brain perfusion and equilibrium dialysis using brain homogenate. It was shown that for reaching a rapid brain equilibrium a high BBB permeability and a low brain tissue binding is required. Kielbas et al., (45) developed a semi-mechanistic model for disposition of atomoxetine and duloxetine in rats using plasma, extracellular brain obtained by microdialysis, terminal CSF and whole brain concentrations following intravenous loading and infusion dosing. The model development was supported by physiological brain parameters obtained from rats (volumes), and in vitro binding (plasma and brain) parameters, while other brain drug disposition parameters were estimated. The model was also used to translate brain disposition from rats to humans by allometry. Westerhout et al., (46), developed a multi-compartment model (including five brain and CSF) for paracetamol in rats using data obtained by serial sampling of blood and microdialysis probes at different regions of CSF and brain. The main focus of the study was to quantify regional drug diffusion and fluid flow processes in the brain, and for this a no transporter substrate compound was used. In the model, the volumes of the brain and CSF compartments as well as brain and CSF flow in rats were fixed to physiological values; however, clearance parameters, which were used to describe the exchange between the compartments were estimated. The model was further used to predict human brain exposure using available human CSF concentration data from the subarchnoid space, and for this human parameter values were substituted for rat values in the model. This model was subsequently extended to include parameters for transporter function and was applied to other compounds and species (47–49). Also, Yamamoto et al., (50,51) extended the model further to include compartments for BBB and BCSFB. A subcellular compartment in the brain was introduced for lysosomes and pH-dependent drug partitioning was also introduced. Model parameterisation were also modified and distinction between system- and drug-specific parameters were introduced to improve the the performance of the models, especially the translation ability. This model which is now called LeiCNS-PK3.0 has been further updated to address other issues such as ionization, brain tissue non-specific binding and passive paracellular transport (10,52). Monine et al., (53) developed a multicompartment CNS model based on anatomy, this was used to describe the PK of antisense oligonucleotides in non-human primate following intrathecal administration to bypass BBB using physiological and drug specific parameters estimated from in vivo data. Vendel et al., (54) developed a mechanistic 3D model to explain local drug concentration within rat brain. The model represents the brain as a 3D cube unit; where the brain ECF is surrounded by capillaries. Drug transport through BBB was described by passive (paracellular and transcellular) and active transport processes, binding kinetics was also accounted for in the model. System and drug specific parameters for capillaries (distance, radius, flow velocity), brain ECF flow velocity, diffusion, BBB permeability, specific and non-specific bindings were presented.

**PBPK Model Linked to IVIVE**

These are mechanistic models that use the knowledge of anatomy and physiology of the brain to determine the structure of the models, combined with IVIVE strategy. The main goal is development of entirely bottom up models, where system parameters are obtained from the literature and drug specific parameters are obtained from in silico and in vitro analysis. The use of IVIVE in the development of models for brain disposition and the strategy for its application based on routinely used in vitro cell lines have been presented and demonstrated through applications to a number of compounds. This approach is mechanistic in nature as it enables dissection of different components of the system, therefore parameters such as in vivo transporter parameter can be translated from in vitro measurements with the aid of appropriate scaling factors. This approach has also been successfully applied in the development of PBPK models for prediction of drugs focusing on hepatic and intestinal components, such as the permeability and transporter uptake and efflux.

Fenneteau et al., (55) developed a PBPK model in wild-type (WT) and mdr1a/1b (-/-) knockout (KO) mice to assess the distribution of drugs in MDR1 expressing tissues. The model focused mostly on heart and brain using tissue concentrations of domperidone. The model also takes into account apparent passive diffusion and active transport across blood tissue membranes. Important components of this model were therefore permeability-surface area product parameters and MDR1 efflux clearances. An approach for extrapolation of these parameters from in vitro Caco-2 monolayer experiments to in vivo estimates was presented. The model provided an insight into drug distribution in MDR1 expressing tissues, it also highlighted the need for quantitative knowledge on transporters from tissues and species for the potential of the approach to be realised. With model developed prior to availability of in vivo data, the authors also discussed the potential use of the approach for different drugs and transporters. Yamamoto et al., (51,56) in the latest update of their PBPK model for brain disposition, also proposed a workflow for the use of in silico and in vitro data to inform active transport parameters across the BBB and BCSFB in the context of their model. Instead of incorporating the expression level and activity of each transporters, a parameter is used to describe the “net effect of active transporter”2. This approach uses reported Kpuu values to derive the contribution of active transport to the overall process. As part of the decision tree proposed, in vitro kinetic parameters from endothelial cells are used when there is
insufficient information for the active process from other sources. Ball et al., (57,58) described PBPK models for CSF and brain disposition of drugs using plasma, CSF and brain ECF concentration data from in situ or microdialysis in rats. The CNS model has compartments for brain vascular, CSF, brain ECF and tissue. Reference values were used for physiological parameters; blood flows and volumes. However, drug transfer across BBB and BCSFB were described using first-order bidirectional parameters with permeability-surface area constants, which were optimised using sensitivity analysis. In addition, a strategy for incorporating a bottom up IVIVE strategy in the prediction of permeability across the BBB using Caco-2 experimental data was also presented. Badhan et al., (59) developed PBPK models for CNS disposition of drugs in rats and mice for a number of compounds, using in vitro permeability data obtained from LLC-PK₁-mdr1a cells, an entirely bottom up approach. This model was further extended to account for distribution into frontal cortex and hippocampus in addition to whole brain ECF (regional brain distribution). The model was developed and validated in rats for carbamazepine and phenytoin and was also further extended to humans (60). Gaohua et al., (38) developed a 4-compartment brain model in human, nested within a whole body-PBPK model and implemented within the Simcyp Simulator (V16). The model is also based on IVIVE of transport parameters across membranes, using both system related parameters in transporter abundance and drug specific parameters in transporter function kinetics. The model was used to predict CSF concentration of paracetamol and phenytoin in humans. An advantage of linking brain model to a whole body-PBPK model is the potentials to assess “what if” scenarios such as transporter mediated DDI, effect of age and disease conditions on drug disposition in the brain. Li et al., (25,39) applied the Gaohua et al., (38) model in Simcyp Simulator (V16,V14) to a first-in-class drug under development, AZD1775 (39) and three cyclin D-cyclin dependent kinase 4 and 6 (CDK4/6) inhibitors (ribociclib, palbociclib, and abemaciclib) in glioblastoma patients (25). Both plasma and brain concentration were adequately predicted in patients with this bottom up approach, using in vitro and in silico data from various experiments including IVIVE of transporter kinetics data obtained from MDCKII (MDCKII-MDR1 and MDCKII–BCRP) systems. Furthermore, Verschijden et al., (61) extended Gaohua et al., (45) model to children by making adjustments for age dependent system and drug dependent parameters, for prediction of drug disposition in CSF of drugs that undergo passive transfer. The model was validated using four anagles (paracetamol, ibuprofen, flurbiprofen and naproxen) and further optimised empirically to account for BBB penetration in paediatric meningitis patients using meropenem as an example.

TRANSPORTERS IN BLOOD-BRAIN BARRIER

This section aims to give an insight into the current knowledge of the expression of transporters in the brains from a drug delivery perspective. Quantitative proteomic techniques have facilitated measurement of the protein levels of drug transporters in the brain. Several transporters are reviewed in terms of their protein expression in rat (Table III) and normal human brain tissue (Table IV) where data is available. Tables III and IV include data for the following ABC transporters: multidrug resistance protein 1 (ABCB1 or MDR1) or P-glycoprotein, the ATP-binding cassette sub-family A member 2 and 8 (ABCA2 or ABC2 and ABCA8 or KIAA0822), the multidrug resistance associated proteins (ABCC1 or MRPI, ABCC4 or MRP4, ABCC6 or MRP6) and the breast cancer resistance protein (ABCG2 or BCRP). Also, data for members of two key solute-linked carrier (SLC or SLCO) superfamilies, SLC22, SLC20A1 and SLC22A, are available, representing the organic cation transporters 1, 3 (OCT1 and OCT3), the organic cation/carnitine transporter 1 (OCTN1), the organic anion transporters (OAT1, OAT2, OAT3, and OAT7) and the organic anion transporting polypeptide (OATP1A2, OATP8, OATP2B1 and OATP1C1). There is limited information available regarding protein expression of transporters within brain tissues measured using labelled isotope standard targeted quantitative methods LC MSMS (3,4,62–69).

Reported abundance data for rats and humans were collated and compared. Overall, expression of Mdr1a or MDR1 was the highest in rats (mean, 18.4 pmol/mg of total protein), while bcrp or BCRP was the highest in human (mean, 4.26 pmol/mg of total protein), and in both species SLC family transporter (Glut1/GLUT1) were the most abundant (mean in rat, 77.3 pmol/mg of total protein; mean in human 188 pmol/mg of total protein, respectively). Among the most highly expressed transporters, more monocarboxylate transporter 1 (Mct1/MCT1) was present in the rats compared to humans (mean, 9.4 versus 2.7 pmol/mg total protein, respectively). This transporter allows the entry of lactate and ketone bodies into the brain. More amino acid transporter (Lat1/LAT1) was expressed in the rats (mean, 2.6 pmol/mg protein) compared to the humans (mean, 0.63 pmol/mg total protein). Most rat abundance data from the individual studies were comparable and within 2-fold of difference except for one study (65), where the transporter abundance values were reported as median (not mean) and not included in calculating the weighted mean from all studies, mostly indicating differences between these studies. Unsurprisingly, protein abundance data for mdr1a or MDR1 and bcrp or BCRP were reported in all collected studies.

Clearly, differences in transporters expression exist between species. For instance, Mdr1a/MDR1 expression was reported to be higher in rats than in humans (>10-fold difference, Fig. 2) and the Mann-Whitney test showed significant differences (p = 0.0043). Bcrp/BCRP was nevertheless shown to be similar between rats and humans (p = 0.25, Fig. 2). Mdr1 protein expression in rat brains within and in between studies was not very variable (mean 18.4 pmol/mg of total protein, % CV 22). Protein expression levels of MDR1 in the human brains were reported not to be statistically different between all studies (<2.5-fold difference). The Mrp/MRP expression are reported in rat (Mrps 1, 4) and human brains (MRP4, 6). Mrp1 and MRP6 were reported in only one study; hence, a comparison was not possible. On the other hand, Mrp4/MRP4, are expressed in both human and rat and the abundance difference was 6-fold lower in human than rat (Fig. 2) and within the 3-fold difference observed between rat studies. Non-parametric statistics test (Mann-Whitney test, p =0.9) showed no
Table III. Absolute Transporter Protein Content in a Panel of Pool Rat Brain Microvessels Quantified by LC-MS/MS

| Protein   | Hoshi et al., (62) a,¥ | Gomez-Zepeda et al., (83) c,¥ | Al Feteisi et al., (3) ¥ | Billington et al., (64) ¥ | Bao et al., (65) a,* | Uchida et al., (66) b, ¥ | Omori et al., (84) b,* |
|-----------|------------------------|-------------------------------|--------------------------|--------------------------|----------------------|------------------------|------------------------|
| Abcb1a/Mdr1a | 19.0 ± 2.0 | 25.2 | 19.6 ± 1.35 | 14.1 ± 7.0 | (15.8 ± 2.56) ¶ | 21.9 | 14.3 ± 0.43 | (69.5 ± 2.1) ¶ | 18.0 ± 0.3 |
| Abcc1/Mrp1    | –          | –    | –           | –           | –                   | –           | –                                |
| Abcc4/Mrp4    | 1.60 ± 0.29 | –    | 2.16 ± 0.74 | 0.73 ± 0.24 | (0.91 ± 0.32) ¶    | –           | 1.63 ± 0.03 | (7.92 ± 0.16) ¶ | 0.99 ± 0.03 |
| Abca8a        | –          | –    | –           | –           | –                   | –           | 2.80 ± 0.16 | (13.6 ± 0.8) ¶ | –                                |
| Abcg2/Bcrp    | 4.15 ± 0.29 | 2.03 | 3.07 ± 0.46 | 2.98 ± 0.66 | (4.07 ± 2.01) ¶    | 4.59 | 6.24 ± 0.06 | (30.4 ± 0.3) ¶ | 4.56 ± 0.21 |
| Slc2a1/Glut1  | 84.0 ± 4.1  | –    | 83.5 ± 4.8 | 45.0 ± 25   | (49 ± 12) ¶          | 201.6 | 81.6 ± 1.35 | (397 ± 7) ¶     | 92.2 ± 1.6 |
| Slc3a2/F2hc   | –          | –    | 16.2 ± 1.90 | –           | –                   | –           | 2.27 ± 0.21 | (11.1 ± 1.0) ¶ | –                                |
| Slc7a5/Lat1   | 3.41 ± 0.74 | –    | 3.70 ± 0.89 | –           | 14.7                | –           | 8.81 ± 0.22 | (42.9 ± 1.1) ¶ | 10.3 ± 0.5 |
| Slc16a1/Mct1  | 11.6 ± 0.6  | –    | 7.08 ± 1.10 | –           | –                   | –           | 3.37 ± 0.12 | (16.4 ± 0.6) ¶ | 0.98 ± 0.05 |
| Slc22a8/Oat3  | 2.13 ± 0.49 | –    | 1.23 ± 0.04 | –           | –                   | –           | 3.34 ± 0.25 | (16.3 ± 1.2) ¶ | 1.61 ± 0.20 |
| SLC27A1/Fatp1 | –          | –    | 1.16 ± 0.62 | –           | –                   | –           | 3.17 ± 0.69 | (15.5 ± 3.4) ¶ | 2.36 |
| Scloda4/Oatpl4 | –          | –    | 1.49 ± 0.09 | 1.99 ± 1.03 | (2.25 ± 0.90) ¶    | –           | 3.18 ± 0.08 | (15.5 ± 0.4) ¶ | 2.40 ± 0.04 |
| Scolc1/Oatplc1| –          | –    | –           | –           | –                   | –           | –                                |

a Data are expressed as median; b Standard error of the mean (S.E.M); c averaged mean value obtained from three different days; ¥protein amount in pmol/mg of total protein; *protein amount in pmol/mg of total membrane protein; ¶protein amount in pmol/g brain tissue.
Table IV. Absolute Transporter Protein Content in a Panel of Individual Human Brain Microvessels Quantified by LC-MS/MS

| Uchida et al., (67)¥ | Shawahna et al., (68)¥ | Al-Majdoub et al., (4)* | Billington et al., (64)† | Storelli et al., (69)¶ | Uchida et al., (66)b,¥ | Bao et al., (65)a,* |
|---------------------|------------------------|-------------------------|-------------------------|------------------------|------------------------|------------------------|
| Mean ± SD (Fold difference) |
| ABCA2/ABC2 | 2.86 ± 0.58 (1.9) | 2.11 ± 0.78 | 0.08 ± 0.03 (4) | – | – | – |
| ABCA8/ABCAS8 | 1.21 ± 0.24 (>1.75) | 0.67 ± 0.23 | – | – | 0.58 ± 0.10 (1.41) (1.35 ± 0.45)¶ | – |
| ABCB1/MDR1 | 6.06 ± 1.69 (2.1) | 3.98 ± 0.88 | 2.58 ± 0.93 (3.2) | 2.86 ± 1.75 (7.57 ± 2.31)¶ | 4.70 ± 2.0 | 3.91 ± 1.38 (2.01) (9.40 ± 4.90)¶ | 3.38 (5.6) |
| ABCC4/MRP4 | 0.19 ± 0.07 (2.6) | 0.31 ± 0.11 | – | – | – | – | – |
| ABCG2/BCRP | 8.14 ± 2.26 (2.9) | 6.15 ± 1.41 | 2.22 ± 0.61 (2.4) | 5.64 ± 4.24 (14.2 ± 5.6)¶ | 10.8 ± 5.4 | 3.39 ± 0.74 (1.5) (7.92 ± 2.78)¶ | 621 (7.4) |
| SLC2A1/GLUT1 | 139 ± 46 (2.7) | – | 21.9 ± 9.80 (9.5) | 559 ± 349 (1477 ± 400)¶ | – | 32.6 ± 8.2 (1.7) (76.1 ± 28.7)¶ | 544 (5.0) |
| SLC7A5 /LAT1 | 0.43 ± 0.09 (>2.03) | 0.80 ± 0.25 | 0.65 ± 0.17 (2.5) | – | – | – | 342 (6.3) |
| SLC16A1/MCT1 | 2.27 ± 0.85 (3.2) | 1.46 ± 0.39 | 5.37 ± 3.73 (13.4) | – | – | 1.59 ± 1.54 (5.8) (290 ± 144)¶ | 519.0 (19.1) |
| SLC16A2/MCT8 | – | 1.31 ± 0.37 | – | – | – | 2.34 ± 0.08 (1.06) (5.71 ± 2.44)¶ | – |
| SLC19A1/RFC | 0.76 ± 0.04 (>1.42) | 0.55 ± 0.18 | 0.18 | – | – | – | – |
| SLC22A1/OCT1 | – | – | 0.56 ± 0.07 (1.5) | – | – | – | – |
| SLC22A3/OCT3 | – | – | 0.62 ± 0.08 (1.5) | – | – | – | – |
| SLC22A4/OCTN1 | – | – | 0.04 ± 0.01 (2.4) | – | – | – | – |
| SLC22A6/OAT1 | – | – | 0.48 ± 0.11 (2.1) | – | – | – | – |
| SLC22AT/OAT2 | – | – | 7.30 ± 3.80 (6.5) | – | – | – | – |
| SLC22A8/OAT3 | – | – | 0.27 ± 0.03 (1.5) | – | – | – | – |
| SLC22A9/OAT7 | – | – | 0.51 ± 0.10 (2.0) | – | – | – | – |
| SLC29A1/ENT1 | 0.57 ± 0.13 (1.85) | 0.86 ± 0.13 | 0.27 ± 0.10 (3.6) | 0.64 ± 0.43 (1.86 ± 0.85)¶ | – | – | – |
| SLC44A1/CTI1 | – | – | 0.88 ± 0.62 (7.9) | – | – | 1.92 ± 0.34 (1.3) (4.85 ± 2.70)¶ | – |
| SLC44A2/CTII2 | – | – | 1.14 ± 0.75 (10.8) | – | – | 5.80 ± 1.47 (1.5) (13.2 ± 3.3)¶ | – |
| S L C O 1 A 2 / | – | – | 0.54 ± 0.10 (1.9) | – | – | – | – |
| OATP1A2 | – | – | 0.46 ± 0.15 (5.5) | – | – | – | – |
| SLC01B3/OATP8 | – | – | 0.40 ± 0.04 | 0.37 ± 0.26 (0.93 ± 0.38)¶ | 0.64 ± 0.43 | – | – |
| SLC02B1/OATP2B1 | – | – | 0.27 ± 0.03 (1.4) | – | – | – | – |
| S L C O 1 C 1 | – | – | – | – | – | – | – |
| OATP1C1 | – | – | – | – | – | – | – |

¥ Data are expressed as median; * Standard error of the mean (S.E.M); † protein amount in pmol/mg of total protein; * protein amount in pmol/mg of total membrane protein; b BA39 (parietal lobe, all other studies either cortex or frontal cortex); ¶ protein amount in pmol/g brain tissue
differences ($p = 0.9$) for Glut1/GLUT1 between rat and human brains (Fig. 2). Between studies however, rat expression data revealed for Glut1 expression a 5-fold difference, while, human expression data showed an over 20-fold difference. Those conflicting results can likely be explained by differences in tissue conditions (i.e., fresh compared to frozen), storage conditions and due to different methodology, that have been used (70) but perhaps more likely to the varying clinical background and post-mortem status of the brain tissues. The expression levels of other transporters such as Lat1, Mct1, Oat3, Oatp1a4, 4f2hc, Fatp1, ABC2, ABCA8, RFC, OATP2B1, MRP4, MCT8, CTL1, and CTL2 were reported in either two or three studies. The reports on most transporters’ expression are comparable between studies; except for expression of 4f2hc, Fatp1, ABC2, CTL2, RFC ranging from 3- and 35.7-fold difference. The expression pattern of Mrp1, Oatp1C1, MRP6, OCT1, OCT3, OCTN1, OAT1, OAT2, OAT3, OAT7, and OATP1C1 is still unclear. These transporters were quantified in only one study (4,66) but there is convincing mRNA evidence for expression of these transporters at BBB (70).

**DISCUSSION AND CONCLUSIONS**

“Science is built of facts as a house is built of stones but an accumulation of facts is no more science than a pile of stones is a house”

Henri Poincare, 1828–1892

More complex PBPK brain models have appeared in the literature recently, reflecting the physiology/anatomy/biology of CNS components. The level of added complexity has been mirroring the intended sophisticated use of the models. The models have helped to turn the sparse and silo pieces of information into an integrated knowledge of the drug disposition in brain.

Since direct measurement of human CNS concentrations is associated with many obstacles, it is important to consider the use of these models. Nonetheless, obtaining appropriate model parameters in order to understand the central kinetics of drugs in humans is a challenge considering various diverse methods used for parameters that are used to describe such models. The IVIVE of permeability by scaling with absolute transporter abundance to the PBPK model is a fundamental aspect in translational abilities to humans whether from *in vitro* experiments or from non-clinical data. Of the IVIVE PBPK models that we could identify, only five model have considered absolute transporter abundance (39,57,59,60,71). Schematic representation of the CNS components of these models are shown in Fig. 3, their properties are summarised in “PBPK model linked to IVIVE” section above and detailed description can be found in the references. With the increasing number of reports on absolute transporter abundance in recent years, this leaves an opportunity to refine these IVIVE-PBPK models so they can be the next generation of tools for a more successful CNS drug development.

Model-informed drug development (MIDD) is no longer just an aspirational idea. There are plenty of evidence to suggest this has become an integral part of modern drug development by leading pharmaceutical companies (72,73) and all the signs are in place from the top regulatory agencies that MIDD is seen not only acceptable approach in many cases but also an encouraged path in certain circumstances (74–77). Therefore, the pharmaceutical industry is arriving at a conjuncture where ability to incorporate the MIDD paradigm into widespread practice is not just an internal scientific decision; it is rather a management strategy issue (78). As with many other management tasks this requires careful assessment of implementation (if MIDD nucleus is not in place) and scaling regarding many other elements (personnel, tools,
Traditionally, modelling and simulation (M&S) have been performed by specialised teams who create bespoke models for each case and have reservations about letting modelling be done by the greater mass of scientists engaged in various stages of drug development. This approach is proven to be too restrictive in the current MIDD environment. As MIDD enters mainstream use during drug development by many pharmaceutical companies, community assessment of various models applied to a certain problem and settling on some selected models that can be used repeatedly by a mass of users with assurance on reproducibly of results become inevitable. This is distinct from the somewhat academic research-oriented use (78).

The current review of PBPK-IVIVE link models suggest that these models are coming to a degree of maturity that they warrant wider applications to real world drug development issues by a wider community of the drug developers that early adopters who take positions in risky frontiers of diverting from the norm. However, there are also gaps in many aspects that need to be addressed, and subsequently get integrated into models rather than remaining as mere facts.

Combining in silico and in vitro data with preclinical in vivo animal experiments and clinical studies in humans provides an opportunity for these IVIVE-PBPK models to be verified through reverse translation (79). This provides robust quality assured models for the next generation of tools used in successful CNS drug development, particularly with added connections to quantitative system pharmacology model (80).

ACKNOWLEDGEMENTS

The authors would like to thank member of Blood Brain Barrier (BBB) Research Project (Genentech, J & J, Merck, Takeda) for useful discussion.

AUTHOR CONTRIBUTION

Y.M., S.N., A.R., H.T, ZA, and KO. wrote the manuscript; Y.M. and Z.A. collected and analyzed the data.

FUNDING

Y.M. received financial support from Mitsubishi Tanabe Pharma Corporation. AR, ZA and KO received financial support from Mitsubishi Tanabe Pharma Corporation, Genentech, J & J, Merck, Takeda.

DECLARATIONS

Conflict of Interest The authors declare no competing interests.
Disclaimer Views expressed in this article are personal opinion of the authors themselves, formed by their scientific judgment, and do not reflect policies, view or required practices of affiliated organizations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

REFERENCES

1. Pammolli F, Righetto L, Abrignani S, Pani L, Pelicci PG, Rabosio E. The endless frontier? The recent increase of R&D productivity in pharmaceuticals. J Transl Med. 2020;18(1):162.
2. Ringel M, Tollman P, Hersch G, Schulze U. Does size matter in R&D productivity? If not, what does? Nat Rev Drug Discov. 2013;12(12):901–2.
3. Al Feteisi H, Al-Majdoub ZM, Achour B, Couto N, Rostami-Hodjegan A, Barber J. Identification and quantification of blood-brain barrier transporters in isolated rat brain microvessels. J Neurochem. 2018;146(6):670–85.
4. Al-Majdoub ZM, Al Feteisi H, Achour B, Warwood S, Neuhoff S, Rostami-Hodjegan A, et al. Proteomic Quantification of Human Blood-Brain Barrier SLC and ABC Transporters in Healthy Individuals and Dementia Patients. Mol Pharm. 2019;16(3):1220–33.
5. Rostami-Hodjegan A. Physiologically Based Pharmacokinetics. Cambridge, UK: Elsevier; 2019.
6. Hammarlund-Udenaes M, Lange ECM, Thorne RG. Drug Delivery to the Brain Physiological Concepts, Methodologies and Approaches. AAPS Advances in the Pharmaceutical Sciences Series. 2014. Springer, New York, NY. pp 3–21.
7. Abbott NJ, Friedman A. Overview and introduction: the blood-brain barrier in health and disease. Epilepsia. 2012;53(Suppl 6):1–6.
8. Maurer MH. Protocomics of brain extracellular fluid (ECF) and cerebrospinal fluid (CSF). Mass Spectrom Rev. 2010;29(1):17–28.
9. Spector R, Keep RF, Robert Snodgrass S, Smith QR, Johanson CE. A balanced view of choroid plexus structure and function: Focus on adult humans. Exp Neurol. 2015;267:78–86.
10. Saleh MAA, de Lange ECM. Impact of CNS Diseases on Drug Delivery to Brain Extracellular and Intracellular Target Sites in Human: A “WHAT-IF” Simulation Study. Pharmaceuticals. 2021;13(1):95.
11. Maurer MH, Berger C, Wolf M, Futterer CD, Feldmann RE Jr, Schwab S, et al. The proteome of human brain microdialysate. Proteome Sci. 2013;11(1):7.
12. Yamamoto Y, Danhof M, de Lange ECM. Microdialysis: the Key to Physiologically Based Model Prediction of Human CNS Target Site Concentrations. AAPS J. 2017;19(4):891–909.
13. Wulkersdorfer B, Wanek T, Bauer M, Zeitlinger M, Muller M, Langer O. Using positron emission tomography to study transporter-mediated drug-drug interactions in tissues. Clin Pharmacol Ther. 2014;96(2):206–13.
14. van Assema DM, Lubberink M, Bauer M, van der Flier WM, Schuit RC, Windhorst AD, et al. Blood-brain barrier P-glycoprotein function in Alzheimer’s disease. Brain. 2012;135(Pt 1):181–9.
15. Ronaldson PT, Davis TP. Targeting blood-brain barrier changes during inflammatory pain: an opportunity for optimizing CNS drug delivery. Ther Deliv. 2011;2(8):1015–41.
16. Lee CM, Farde L. Using positron emission tomography to facilitate CNS drug development. Trends Pharmacol Sci. 2006;27(6):310–6.
17. Fridén M. Development of Methods for Assessing Unbound Drug Exposure in the Brain. In vivo, in vitro and in silico. PhD Thesis Summary, Faculty of Pharmacy, Uppsala Universitet, Sweden. 2010. pp 1–57.
18. Kakae A, Terasaki T, Sugiyama Y. Brain Efflux Index as a Novel Method of Analyzing Efflux Transport at the Blood-Brain Barrier. J Pharmacol Exp Ther. 1996;277(3):1550–9.
19. Friden M, Ducrozet F, Middleton B, Antonsson M, Bredberg U. Hammarlund-Udenaes M. Development of a high-throughput brain slice method for studying drug distribution in the central nervous system. Drug Metab Dispos. 2009;37(6):1226–33.
20. Kalvass JC, Maurer TS. Influence of nonspecific brain and plasma binding on CNS: exposure implications for rational drug discovery. Biopharm Drug Dispos. 2002;23(8):327–38.
21. Takasato Y, Rapoport SI, Smith JR. An In Situ brain perfusion technique to study cerebrovascular transport in the rat. Am J Physiol. 1984;247(3 Pt 2):H484–93.
22. Fenstermacher J, Gross P, Sposito N, Acuff V, Pettersen S, Gruber K. Structural and functional variations in capillary systems within the brain. Ann N Y Acad Sci. 1989;529:21–30.
23. Dukes JD, Whitley P, Chalmers AD. The MDCK variety pack: choosing the right strain. BMC Cell Biol. 2011;12:43.
24. Hellinger E, Veszelka S, Toth AE, Walter F, Kittel A, Bakk ML, et al. Comparison of brain capillary endothelial cell-based and epithelial (MDCK-MR1, Caco-2, and VB-Caco-2) cell-based surrogate blood-brain barrier penetration models. Eur J Pharm Biopharm. 2012;82(2):340–51.
25. Li J, Jiang J, Wu J, Bao X, Sanai N. Physiologically Based Pharmacokinetic Modeling of Central Nervous System Pharmacokinetics of CDK4/6 Inhibitors to Guide Selection of Drug and Dosing Regimen for Brain Cancer Treatment. Clin Pharmacol Ther. 2021;109(2):494–506.
26. Verscheijden LF, Litjens CH, Koenderink JB, Mathijssen RHJ, Verbeck MM, de Wildt SN, Russel FGM. Physiologically based pharmacokinetic/pharmacodynamic model for the prediction of morphine brain disposition and analgesia in adults and children. PLoS Comput Biol. 2021;17(3):e1008786.
27. Oldendorf WH, Partridge WM, Braun LD, Crane PD. Measurement of Cerebral Glucose Utilization Using Washout After Carotid Injection in the Rat. J Neurochem. 1982;38(5):1413–8. https://doi.org/10.1111/j.1471-4159.1982.tb07920.x.
28. Di L, Kerns EH, Fan K, McConnell OJ, Carter GT. High throughput artificial membrane permeability assay for blood-brain barrier. Eur J Med Chem. 2003;38(3):223–32.
29. Bicker J, Alves G, Fortuna A, Soares-da-Silva P, Falcao A. A new PAMPA model using an in-house brain lipid extract for screening the blood-brain barrier permeability of drug candidates. Int J Pharm. 2016;501(1-2):102–11.
30. Konovalov DA, Coomans D, Deconinck E, Heyden YV. Benchmarking of QSAR models for blood-brain barrier permeation. J Chem Inf Model. 2007;47(4):1648–56.
31. Carpenter TS, Kirshner DA, Lau EY, Wong SE, Niimeyer JP, Lightstone FC. A method to predict blood-brain barrier permeability of drug-like compounds using molecular dynamics simulations. Biophys J. 2014;107(3):e360–41.
32. Sato S, Matsumiya K, Tohyama K, Kosugi Y. Translational CNS Proteome Sci. 2003;1(1):7.
33. Al Feteisi H, Al-Majdoub ZM, Achour B, Couto N, Rostami-Hodjegan A, Barber J. Identification and quantification of blood-brain barrier transporters in isolated rat brain microvessels. J Neurochem. 2018;146(6):670–85.
34. Al-Majdoub ZM, Al Feteisi H, Achour B, Warwood S, Neuhoff S, Rostami-Hodjegan A, et al. Proteomic Quantification of Human Blood-Brain Barrier SLC and ABC Transporters in Healthy Individuals and Dementia Patients. Mol Pharm. 2019;16(3):1220–33.
35. Rostami-Hodjegan A. Physiologically Based Pharmacokinetics. Cambridge, UK: Elsevier; 2019.
36. Hammarlund-Udenaes M, Lange ECM, Thorne RG. Drug Delivery to the Brain Physiological Concepts, Methodologies and Approaches. AAPS Advances in the Pharmaceutical Sciences Series. 2014. Springer, New York, NY. pp 3–21.
37. Abbott NJ, Friedman A. Overview and introduction: the blood-brain barrier in health and disease. Epilepsia. 2012;53(Suppl 6):1–6.
38. Maurer MH. Protocomics of brain extracellular fluid (ECF) and cerebrospinal fluid (CSF). Mass Spectrom Rev. 2010;29(1):17–28.
39. Spector R, Keep RF, Robert Snodgrass S, Smith QR, Johanson CE. A balanced view of choroid plexus structure and function: Focus on adult humans. Exp Neurol. 2015;267:78–86.
40. Saleh MAA, de Lange ECM. Impact of CNS Diseases on Drug Delivery to Brain Extracellular and Intracellular Target Sites in Human: A “WHAT-IF” Simulation Study. Pharmaceuticals. 2021;13(1):95.
41. Maurer MH, Berger C, Wolf M, Futterer CD, Feldmann RE Jr, Schwab S, et al. The proteome of human brain microdialysate. Proteome Sci. 2003;1(1):7.
42. Yamamoto Y, Danhof M, de Lange ECM. Microdialysis: the Key to Physiologically Based Model Prediction of Human CNS Target Site Concentrations. AAPS J. 2017;19(4):891–909.
43. Wulkersdorfer B, Wanek T, Bauer M, Zeitlinger M, Muller M, Langer O. Using positron emission tomography to study
34. Liu X, Tu M, Kelly RS, Chen C, Smith BJ. Development of a computational approach to predict blood-brain barrier permeability. Drug Metab Dispos. 2004;32(1):132–9.

35. Shaker B, Yu M-S, Song JS, Ahn S, Ryu JY, Oh K-S, Na D. LightBBB: computational prediction model of blood–brain barrier penetration based on LightGBM. Bioinformatics. 2020;37(8):1135–9.

36. Aarons L. Physiologically based pharmacokinetic modelling: a sound mechanistic basis is needed. Br J Clin Pharmacol. 2005;60(6):581–3.

37. Tسامандурас N, Ростами-Ходжеган A, Aarons L. Combining the “bottom up” and “top down” approaches in pharmacokinetic modelling: fitting PBPK models to observed clinical data. Br J Clin Pharmacol. 2015;79(1):48–55.

38. Gaohua L, Neuhoff S, Johnson TN, Rostami-Hodjegan A, Aarons L. Combining physiologically based pharmacokinetic and pharmacodynamical approach. Eur J Pharmacol. 2016;741:224–39.

39. Li J, Wu J, Bao X, Honea N, Xie Y, Kim S, Sparreboom A, Bao X, Wu J, Xie Y, Kim S, Sparreboom A, Kurkinen W, Bakshi S, Aranazana-Clement V, Marchand S, Daiyot-Fizelier C, Couet W, Danhof M, van Hasselt JGC, de Lange EC. A physiologically based pharmacokinetic model for prediction of drug distribution in the brain. J Pharmacokinet Pharmacodyn. 2020;11:238–46.

40. Groenendaal D, Freijer J, de Mik D, Bouw MR, Danhof M, de Lange EC. Population pharmacokinetic modelling of non-linear brain distribution of morphine: influence of active saturable influx and P-glycoprotein mediated efflux. Br J Pharmacol. 2007;151(5):701–12.

41. Ooie T, Terasaki T, Suzuki H, Sugiyama Y. Kinetic Evidence for Flurathane Induced P-gp Functionality on Non-Steady State Relationships between Different Species - in Vitro. J Pharmacokinet Pharmacodyn. 2013;40(3):327–43.

42. Yamamoto Y, Valitato PA, Wang YC, Huntjens DR, Proost JH, Veerman A, Kurkinen W, et al. Prediction of human CNS pharmacokinetics using a physiologically-based pharmacokinetic modeling approach. Eur J Pharm Sci. 2018;112:168–79.

43. Saleh MAA, Loo CF, Ellassa-Schaap J, De Lange ECM. Lumbar cerebrospinal fluid-to-brain drug fluxes: context-specific insights from LeCNS-PK3.0 simulations. J Pharmacokinet Pharmacodyn. 2021;48:725–41.

44. Monine M, Norris D, Wang Y, Nesterov I. A physiologically-based pharmacokinetic model to describe antiseizure olgunegenolide distribution after intrathecal administration. J Pharmacokinet Pharmacodyn. 2021;48:639–53.

45. Vendel E, Rottschäfer V, de Lange ECM. A 3D brain unit model to further improve prediction of local drug distribution within the brain. PLoS One. 2019;15(9):e0238397.

46. Frédérique Fenetteau JT, Couture L, Michaud V, Li J, Nekka F. Assessing drug distribution in tissues expressing P-glycoprotein through physiologically based pharmacokinetic modeling: model structure and parameters determination. Theor Biol Med Model. 2009;6(2):1–13.

47. Yamamoto Y, Valitato PA, van den Berg D-J, Hartman R, van den Brink W, Yoshida T, Hunter DR, Proost JH, Veerman A, et al. Prediction of human CNS pharmacokinetics using a physiologically-based pharmacokinetic modeling approach. Eur J Pharm Sci. 2018;112:168–79.

48. Saleh MAA, Loo CF, Ellassa-Schaap J, De Lange ECM. Lumbar cerebrospinal fluid-to-brain drug fluxes: context-specific insights from LeCNS-PK3.0 simulations. J Pharmacokinet Pharmacodyn. 2021;48:725–41.

49. Monine M, Norris D, Wang Y, Nesterov I. A physiologically-based pharmacokinetic model to describe antiseizure olgunegenolide distribution after intrathecal administration. J Pharmacokinet Pharmacodyn. 2021;48:639–53.

50. Vendel E, Rottschäfer V, de Lange ECM. A 3D brain unit model to further improve prediction of local drug distribution within the brain. PLoS One. 2019;15(9):e0238397.

51. Frédérique Fenetteau JT, Couture L, Michaud V, Li J, Nekka F. Assessing drug distribution in tissues expressing P-glycoprotein through physiologically based pharmacokinetic modeling: model structure and parameters determination. Theor Biol Med Model. 2009;6(2):1–13.
67. Uchida Y, Ohtsuki S, Katsukura Y, Ikeda C, Suzuki T, Kamiie J, Terasaki T. Quantitative targeted absolute proteomics of human blood-brain barrier transporters and receptors. J Neurochem. 2011;117(2):333–45.
68. Shawahna R, Uchida Y, Decleves X, Ohtsuki S, Yousif S, Dauchy S, et al. Transcriptomic and quantitative proteomic analysis of transporters and drug metabolizing enzymes in freshly isolated human brain microvessels. Mol Pharm. 2011;8(4):1332–41.
69. Storelli F, Billington S, Kumar AR, Unadkat JD. Abundance of P-Glycoprotein and Other Drug Transporters at the Human Blood-Brain Barrier in Alzheimer’s Disease: A Quantitative Targeted Proteomic Study. Clin Pharmacol Ther. 2021;109(3):667–75.
70. Yousif S, Marie-Claire C, Roux F, Scherrmann JM, Decleves X. Expression of drug transporters at the blood-brain barrier using an optimized isolated rat brain microvessel strategy. Brain Res. 2007;1134(1):1–11.
71. Johnson M, Kozlikska M, Pilla Reddy V, Vermeulen A, Barton HA, Grimwood S, de Greef R, Groothuis GMM, Danhof M, Proost JH. Translational Modeling in Schizophrenia: Predicting Human Dopamine D2 Receptor Occupancy. Pharm Res. 2016;33(4):1003–17.
72. Nijsen M, Wu F, Bansal L, Bradshaw-Pierce E, Chan JR, Liedeker BM, Metcalf IT, Schroeder P, Schuck E, Tsai A, Xu C, Chimalakonda A, le K, Penney M, Topp B, Yamada A, Spiller ME. Preclinical QSP Modeling in the Pharmaceutical Industry: An IQ Consortium Survey Examining the Current Landscape. CPT Pharmacometrics Syst Pharmacol. 2018;7(3):135–46.
73. Workgroup EM, Marshall SF, Burghaus R, Cosson V, Cheung SY, Chenel M, et al. Good Practices in Model-Informed Drug Discovery and Development: Practice, Application, and Documentation. CPT Pharmacometrics Syst Pharmacol. 2016;5(3):93–122.
74. Li L, Han H, Wang J, Wei C, Wang Y, Li M, Zhou Y, Yang J. Model Informed Drug Development and Regulation in China: Challenges and Opportunities. CPT Pharmacometrics Syst Pharmacol. 2019;8(2):59–61.
75. Manolis E, Brogren J, Cole S, Hay JL, Nordmark A, Karlsson KE, Lentz F, Benda N, Wangorsch G, Pons G, Zhao W, Gigante V, Serone F, Standing JF, Dokoumetzidis A, Vakkilainen J, van den Heuvel M, Mangas Sanjuan V, Taminiau J, et al. Commentary on the MID3 Good Practices Paper. CPT Pharmacometrics Syst Pharmacol. 2017;6(7):416–7.
76. Sato M, Ochiai Y, Kijima S, Nagai N, Ando Y, Shikano M, Nomura Y. Quantitative Modeling and Simulation in PMDA: A Japanese Regulatory Perspective. CPT Pharmacometrics Syst Pharmacol. 2017;6(7):413–5.
77. Wang Y, Zhu H, Madabushi R, Liu Q, Huang SM, Zineh I. Model-Informed Drug Development: Current US Regulatory Practice and Future Considerations. Clin Pharmacol Ther. 2019;105(4):899–911.
78. Rostami-Hodjegan A, Bois FY. Opening a debate on open-source modeling tools: Pouring fuel on fire versus extinguishing the flare of a healthy debate. CPT Pharmacometrics Syst Pharmacol. 2021;10(5):420–7.
79. Rostami-Hodjegan A. Reverse Translation in PBPK and QSP: Going Backwards in Order to Go Forward With Confidence. Clin Pharmacol Ther. 2018;103(2):224–32.
80. Geerts H, Wikswo J, van der Graaf PH, Bai JF, Gaetani C, Bennett D, Swalley SE, Schuck E, Kaldurah-Daouk R, Isaoun K, Pellevymounter M. Quantitative Systems Pharmacology for Neuroscience Drug Discovery and Development: Current Status, Opportunities, and Challenges. CPT Pharmacometrics Syst Pharmacol. 2020;9(1):5–20.
81. Geldof M, Freijer J, van Beijsterveldt L, Danhof M. Pharmacokinetic modeling of non-linear brain distribution of fluvoxamine in the rat. Pharm Res. 2008;25(4):792–804.
82. Ball K, Bouzom F, Scherrmann JM, Walther B, Decleves X. Comparing translational population-PBPK modelling of brain microdialysis with bottom-up prediction of brain-to-plasma distribution in rat and human. Biopharm Drug Dispos. 2014;35(7):845–99.
83. Gomez-Zepeda D, Chaves C, Taghi M, Sergent P, Liu WQ, Chluon C, Vidal M, Picard M, Thioulouse E, Brouin I, Guerrero IC, Scherrmann JM, Parmentier Y, Decleves X, Menet MC. Targeted unlabeled multiple reaction monitoring analysis of cell markers for the study of sample heterogeneity in isolated rat brain cortical microvessels. J Neurochem. 2017;142(4):597–609.
84. Omori K, Tachikawa M, Hirose S, Tani A, Akanuma S-I, Hosooya K-I, et al. Developmental changes in transporter and receptor protein expression levels at the rat blood-brain barrier based on quantitative targeted absolute proteomics. Drug Metab Pharmacokinet. 2020;35(1):117–23.

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.